US Ebola vaccine to be trialed on humans
An experimental US Ebola vaccine is to be trialed on humans at the country’s National Institutes of Health (NIH)’s campus in Bethesda, Maryland next week.
The NIH announced that it is launching the safety trial on a vaccine developed by the agency’s National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline.
It will test 20 healthy adult volunteers to see if the vaccine is safe and triggers an adequate response in their immune systems.
NIAID Director Dr. Anthony Fauci said the vaccine had worked in tests on monkeys.
“All the other monkeys, the control monkeys, that were given a lethal dose of Ebola all died. All of the animals who were vaccinated survived. So the results were pretty crisp and clear cut,” he said.
Later in September, the NIH and a British team will test that vaccine on volunteers in the United Kingdom, Gambia, and Mali.
Ebola spreads through contact with bodily fluids such as blood, saliva, and sweat. It has killed around two-thirds of those it has infected over the last four decades, with two outbreaks registering fatality rates approaching 90 percent.
There is currently no known cure for Ebola. Guinea, Liberia, and Sierra Leone are grappling with the disease, which has also spread to Nigeria.
According to the World Health Organization, the Ebola epidemic has killed more than 1,400 people in four West African countries – Guinea, Liberia, Sierra Leone and Nigeria.
HN/HJL